

# Vipul Jairath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918044/publications.pdf>

Version: 2024-02-01

175  
papers

5,160  
citations

81900

39  
h-index

106344

65  
g-index

179  
all docs

179  
docs citations

179  
times ranked

5538  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 727-736.e2.	4.4	16
2	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	4.4	6
3	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	2.3	4
4	Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 364-372.	1.9	28
5	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
6	Underrepresentation of Minorities and Underreporting of Race and Ethnicity in Crohn's Disease Clinical Trials. <i>Gastroenterology</i> , 2022, 162, 338-340.e2.	1.3	13
7	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	3.7	6
8	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.4	13
9	No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3115-3123.	2.3	2
10	Risk Stratification in Cancer Patients with Acute Upper Gastrointestinal Bleeding: Comparison of Glasgow-Blatchford, Rockall and AIMS65, and Development of a New Scoring System. <i>Clinical Endoscopy</i> , 2022, , .	1.5	4
11	Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1293-1295.	1.9	4
12	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i434-i435.	1.3	0
13	The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1321-1334.	1.3	4
14	Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2598-2606.	4.4	10
15	Design of Clinical Trials for Mild to Moderate Crohn's Disease. <i>Gastroenterology</i> , 2022, , .	1.3	1
16	Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression. <i>Inflammatory Bowel Diseases</i> , 2022, , .	1.9	0
17	Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. , 2022, 10, e004560.		9
18	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15

#	ARTICLE	IF	CITATIONS
19	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. Gastroenterology and Hepatology, 2022, 18, 14-27.	0.1	0
20	Comparison of Risk Scores for Lower Gastrointestinal Bleeding. JAMA Network Open, 2022, 5, e2214253.	5.9	12
21	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. The Cochrane Library, 2021, 2021, CD013256.	2.8	13
22	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clinical Gastroenterology and Hepatology, 2021, 19, 2031-2045.e11.	4.4	121
23	Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, e47-e48.	1.9	4
24	High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. Inflammatory Bowel Diseases, 2021, 27, e59-e60.	1.9	7
25	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Alimentary Pharmacology and Therapeutics, 2021, 53, 784-793.	3.7	18
26	Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. Inflammatory Bowel Diseases, 2021, 27, e65-e65.	1.9	6
27	Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	1
28	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 711-722.	3.0	8
29	The Impact of Multidisciplinary Conferences on Treatment Plans for Patients With Inflammatory Bowel Disease in a Tertiary Canadian Centre. Journal of the Canadian Association of Gastroenterology, 2021, 4, 284-289.	0.3	3
30	Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators. Inflammatory Bowel Diseases, 2021, 27, e98-e98.	1.9	2
31	OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. Journal of Crohn's and Colitis, 2021, 15, S001-S002.	1.3	23
32	Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier's Disease in a Patient With Ulcerative Colitis. Inflammatory Bowel Diseases, 2021, 27, e132-e133.	1.9	2
33	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	1.3	57
34	Challenges and Opportunities in IBD Clinical Trial Design. Gastroenterology, 2021, 161, 400-404.	1.3	11
35	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. Gastroenterology, 2021, 161, 778-784.	1.3	0
36	Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Diagnostics, 2021, 11, 1926.	2.6	9

#	ARTICLE	IF	CITATIONS
37	A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. Health Technology Assessment, 2021, 25, 1-86.	2.8	4
38	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2021, 19, 608.	0.8	1
39	Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials " is it ready for prime time yet? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 948-949.	3.7	0
40	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis" authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 957-958.	3.7	0
41	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Alimentary Pharmacology and Therapeutics, 2021, 53, 1108-1117.	3.7	13
42	Editorial: standardising inclusion and outcome criteria for pouchitis" a fragile consensus perhaps but a first step in the right direction. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1149-1150.	3.7	0
43	Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 69-81.e3.	4.4	137
44	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clinical Gastroenterology and Hepatology, 2020, 18, 1121-1132.e2.	4.4	18
45	Global burden of inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 2-3.	8.1	187
46	Reporting of randomized factorial trials was frequently inadequate. Journal of Clinical Epidemiology, 2020, 117, 52-59.	5.0	19
47	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 424-431.e7.	4.4	15
48	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 435-445.	3.7	26
49	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology, 2020, 159, 2013-2018.e7.	1.3	16
50	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. Current Treatment Options in Gastroenterology, 2020, 18, 442-461.	0.8	2
51	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Alimentary Pharmacology and Therapeutics, 2020, 52, 1008-1016.	3.7	27
52	Adalimumab for maintenance of remission in Crohn's disease. The Cochrane Library, 2020, 2020, CD012877.	2.8	6
53	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. American Journal of Gastroenterology, 2020, 115, 885-894.	0.4	15
54	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Alimentary Pharmacology and Therapeutics, 2020, 52, 481-491.	3.7	10

#	ARTICLE	IF	CITATIONS
55	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	4.4	48
56	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2354-2372.	2.3	23
57	Editorial: histologic normalisation in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 399-401.	3.7	1
58	Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD012381.	2.8	8
59	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , 2020, 7, 35-64.	2.3	49
60	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	3.7	33
61	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	4.4	4
62	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	3.7	5
63	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , 2019, 68, 1162-1168.	12.1	45
64	Letter: preoperative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 467-468.	3.7	1
65	No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 416-424.	3.7	12
66	Letter: immunogenicity of anti-TNF in elderly IBD patients" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 337-337.	3.7	0
67	Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. <i>Trials</i> , 2019, 20, 467.	1.6	12
68	Editorial: evolving histological assessment of NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1245-1246.	3.7	0
69	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	27
70	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1086-1093.	3.7	27
71	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1233-1244.e5.	1.3	58
72	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	3.7	66

#	ARTICLE	IF	CITATIONS
73	Editorial: combination immunosuppressive therapy to treat Crohn's disease "ready for all age groups? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1529-1529.	3.7	0
74	Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 104-105.	3.7	0
75	Most noninferiority trials were not designed to preserve active comparator treatment effects. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 82-89.	5.0	19
76	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	3.7	21
77	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	3.7	24
78	Editorial: blood transfusion for lower gastrointestinal bleeding-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 957-957.	3.7	0
79	Efficacy of Endoscopic Dilatation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2514-2522.e8.	4.4	31
80	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2374-2376.e2.	4.4	15
81	Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. <i>Gut</i> , 2019, 68, 776-789.	12.1	195
82	Outcomes following restrictive or liberal red blood cell transfusion in patients with lower gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 919-925.	3.7	14
83	What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101601.	2.4	11
84	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.4	42
85	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 364-374.	3.7	3
86	Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 537-545.	3.7	9
87	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 63-70.	8.1	15
88	Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1276-1284.e3.	4.4	27
89	Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. <i>Gut</i> , 2018, 67, gutjnl-2016-313428.	12.1	122
90	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 940-950.	3.7	51

#	ARTICLE	IF	CITATIONS
91	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1879-1892.	4.4	101
92	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 129-146.	0.8	64
93	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	1.9	47
94	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
95	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
96	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , 2018, 67, 61-69.	12.1	34
97	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 167-177.	1.3	44
98	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	4.4	44
99	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	1.3	76
100	P473 Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S343-S343.	1.3	2
101	Outcome measures in clinical trials of treatments for acute severe haemorrhage. <i>Trials</i> , 2018, 19, 533.	1.6	25
102	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1251-1259.	3.7	6
103	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018, 113, 1197-1205.	0.4	40
104	The emerging role of histologic disease activity assessment in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 887-898.	1.0	93
105	Editorial: aminosalicylates in Crohn's disease—prevalence, risks, costs and time to reassess? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 489-489.	3.7	0
106	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	3.7	12
107	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29
108	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , 2018, 459, 50-54.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Physiciansâ€™ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohnâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563.	2.3	12
110	Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. <i>Trials</i> , 2018, 19, 265.	1.6	9
111	Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (<sc>EoE</sc>â€™<sc>HSS</sc>)â€™an important first step. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1714-1715.	3.7	2
112	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
113	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 617-630.	3.7	68
114	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1021-1042.	3.7	41
115	Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 354-360.	8.1	131
116	Editorial: the impact of the placebo effect in Crohn's disease â€™ author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1472-1472.	3.7	1
117	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 3-15.	3.7	97
118	Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 213-224.	3.7	210
119	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , 2017, 2017, CD011256.	2.8	42
120	Letter: dose optimising infliximab in acute severe ulcerative colitis â€™ authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1170-1171.	3.7	1
121	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017, , .	2.8	10
122	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1658-1669.	0.4	43
123	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	2.2	7
124	Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 635-643.	8.1	99
125	Editorial: gut selective immunosuppressionâ€™is it a double edged sword? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 374-374.	3.7	0
126	Editorial: faecal microbiota transplantation for ulcerative colitisâ€™not quite there yet? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 631-632.	3.7	0



#	ARTICLE	IF	CITATIONS
127	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 516-528.	3.7	53
128	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	1.3	19
129	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017, 9, CD011572.	2.8	13
130	Patterns of blood component use in cirrhosis: a nationwide study. <i>Liver International</i> , 2016, 36, 522-529.	3.9	49
131	Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. <i>Hepatology</i> , 2016, 64, 682-683.	7.3	2
132	Oral janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, , .	2.8	1
133	Study protocol: first nationwide comparative audit of acute lower gastrointestinal bleeding in the UK. <i>BMJ Open</i> , 2016, 6, e011752.	1.9	5
134	Treatment Targets in Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 151, 1030-1032.	1.3	0
135	Acute severe ulcerative colitis: from pathophysiology to clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 654-664.	17.8	129
136	Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives. <i>The Cochrane Library</i> , 2016, , .	2.8	2
137	Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 38-43.	5.0	9
138	Efficient Early Drug Development for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1056-1060.	1.3	19
139	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
140	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1200-1210.	3.7	115
141	Extending evidence for the use of tranexamic acid from traumatic haemorrhage to other patients with major bleeding: do we need more than one haemorrhage protocol? The case of gastrointestinal bleeding. <i>Transfusion Medicine</i> , 2015, 25, 198-200.	1.1	1
142	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1158-1169.	3.7	49
143	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. <i>Lancet</i> , 2015, 386, 137-144.	13.7	207
144	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. <i>BMJ Open</i> , 2015, 5, e007230-e007230.	1.9	57

#	ARTICLE	IF	CITATIONS
145	Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. <i>Trials</i> , 2014, 15, 456.	1.6	69
146	RESTRICTIVE VERSUS LIBERAL BLOOD TRANSFUSION FOR ACUTE UPPER GASTROINTESTINAL BLEEDING (TRIGGER): PRAGMATIC, CLUSTER RANDOMISED, FEASIBILITY TRIAL. <i>Emergency Medicine Journal</i> , 2014, 31, 780.1-780.	1.0	3
147	HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 450.	1.6	79
148	OC-053â€¦Results Of The Uk Multi-regional Audit Of Blood Component Use In Cirrhosis. <i>Gut</i> , 2014, 63, A26.1-A26.	12.1	0
149	Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit. <i>Digestive and Liver Disease</i> , 2014, 46, 419-426.	0.9	81
150	Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 166-171.	1.3	23
151	New oral anticoagulants in patients with atrial fibrillation. <i>Lancet</i> , The, 2014, 384, 24.	13.7	0
152	Poor Outcomes in Hospitalized Patients With Gastrointestinal Bleeding: Impact of Baseline Risk, Bleeding Severity, and Process of Care. <i>American Journal of Gastroenterology</i> , 2014, 109, 1603-1612.	0.4	21
153	Is Treatment of Moderate Thrombocytopenia Indicated for Patients With HCV Infection and Cirrhosis?. <i>Gastroenterology</i> , 2014, 147, 254.	1.3	0
154	PTU-185â€¦Update On The Halt-it Trial Progress: Tranexamic Acid For The Treatment Of Gastrointestinal Haemorrhage â€œ An International, Randomised, Double Blind Placebo Controlled Trial. <i>Gut</i> , 2014, 63, A120.1-A120.	12.1	1
155	Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 316-322.	3.7	54
156	PWE-184â€¦Prevalence, management and outcomes of patients with coagulopathy following acute non-variceal upper gastrointestinal bleeding. <i>Gut</i> , 2012, 61, A371.1-A371.	12.1	0
157	Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. <i>Endoscopy</i> , 2012, 44, 723-730.	1.8	84
158	Improving outcomes from acute upper gastrointestinal bleeding: Table 1. <i>Gut</i> , 2012, 61, 1246-1249.	12.1	29
159	Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity. <i>The Cochrane Library</i> , 2012, , .	2.8	2
160	PWE-295â€¦Thrombin generation is normal in cirrhotics with acute variceal haemorrhage: results from a prospective study. <i>Gut</i> , 2012, 61, A418-A418.	12.1	4
161	PWE-294â€¦Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy. <i>Gut</i> , 2012, 61, A417.2-A417.	12.1	2
162	National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding. <i>British Journal of Surgery</i> , 2012, 99, 1672-1680.	0.3	60

#	ARTICLE	IF	CITATIONS
163	Why Do Mortality Rates for Nonvariceal Upper Gastrointestinal Bleeding Differ around the World? A Systematic Review of Cohort Studies. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 537-543.	1.7	41
164	OC-069...Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic. <i>Gut</i> , 2012, 61, A30.1-A30.	12.1	2
165	The case for universal access to tranexamic acid. <i>ISBT Science Series</i> , 2012, 7, 173-176.	1.1	1
166	The Overall Approach to the Management of Upper Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 657-670.	1.4	11
167	Mortality From Acute Upper Gastrointestinal Bleeding in the United Kingdom: Does It Display a "Weekend Effect"? <i>American Journal of Gastroenterology</i> , 2011, 106, 1621-1628.	0.4	74
168	Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. <i>Transfusion</i> , 2011, 51, 1940-1948.	1.6	25
169	OC-023...Can we predict length of stay in patients admitted with acute upper gastrointestinal bleeding?. <i>Gut</i> , 2010, 59, A10.1-A10.	12.1	0
170	PTH-020...Acute upper gastrointestinal bleeding: why do patients die?. <i>Gut</i> , 2010, 59, A130.2-A131.	12.1	0
171	PTH-019...Mortality from acute upper gastro-intestinal bleeding in the UK: does it display a "weekend effect"? <i>Gut</i> , 2010, 59, A130.1-A130.	12.1	0
172	Infliximab for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
173	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
174	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <i>The Cochrane Library</i> , 0, , .	2.8	5
175	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. <i>Inflammatory Bowel Diseases</i> , 0, , .	1.9	0